In Vitro Efficacy Testing Services for Liver Injury
Drug R&D Solutions

In Vitro Efficacy Testing Services for Liver Injury

Inquiry

We provide robust and sensitive in vitro screening and characterization platforms for accelerating the discovery and screening of potential therapies for Liver Injury. Our services enable comprehensive evaluation of candidate compounds by assessing their effects on hepatocyte viability, function, and response to injury. Key targets and pathways analyzed include cytochrome P450 enzymes, mitochondrial function, oxidative stress markers, and apoptotic signaling. We are equipped to investigate critical pathological processes such as hepatotoxicity, inflammation, oxidative stress, and cell death relevant to acute and chronic liver injury.

Our in vitro efficacy testing services for Liver Injury encompass a diverse array of assay platforms, including cell-based, enzymatic, and molecular detection methods. These assays are designed to measure cellular viability, enzymatic activity, biomarker expression, and molecular interactions, providing comprehensive insight into compound efficacy and toxicity profiles.

ATP assay: Measures cellular ATP levels as an indicator of cell viability and metabolic activity, commonly used to assess cytotoxicity in hepatocytes.

Acetyl-Arg-Gly-Lys (Ac)-7-amido-4-methylcoumarin as substrate: Utilizes a fluorogenic substrate to detect specific protease or enzymatic activities, aiding in the evaluation of cellular injury or enzyme inhibition.

Cell-based assay: Employs cultured liver cells to assess direct compound effects on cell health, function, and injury markers in a physiologically relevant context.

Chemiluminescent assay: Detects target molecules or enzyme activities using light emission, providing sensitive quantification of biomarkers or cellular responses.

Flow cytometry assay: Enables multiparametric analysis of individual cells, including viability, apoptosis, and surface marker expression, to profile injury mechanisms.

Fluorescent assay: Uses fluorescent probes or substrates to monitor cellular events, enzyme activities, or biomarker levels, offering rapid and quantitative analysis.

Luciferine/luciferase assay: Measures bioluminescence resulting from luciferase activity, often used for reporting gene expression or cell viability in hepatotoxicity studies.

RNA assay: Quantifies gene expression changes in response to treatment, enabling mechanistic insights into pathways activated during liver injury.

Radioactivity assay: Employs radiolabeled substrates or tracers to track molecular interactions or metabolic processes with high sensitivity.

SRC-1 peptide recruitment assay: Assesses the recruitment of steroid receptor coactivator-1 to nuclear receptors, informing on transcriptional regulation relevant to liver injury.

SRC-2-2 peptide recruitment assay: Evaluates the interaction of steroid receptor coactivator-2-2 with nuclear receptors, contributing to the understanding of gene regulation in hepatic responses.

We measure a range of pharmacological parameters such as potency, efficacy, binding affinity, and minimal effective or inhibitory concentrations. These parameters are critical for comparing candidate compounds, optimizing lead selection, and understanding therapeutic windows in drug development for liver injury.

EC-50: The concentration of a compound that produces 50% of its maximal effect, indicating potency in efficacy assays.

IC-50: The concentration required to inhibit a biological process or enzyme activity by 50%, used to assess inhibitory strength.

Kd: The equilibrium dissociation constant, reflecting the binding affinity between a compound and its target; lower Kd denotes stronger binding.

MEC: Minimum Effective Concentration, the lowest concentration at which a compound exerts a significant biological effect, important for dose selection.

MIC: Minimum Inhibitory Concentration, the smallest concentration that prevents a specified biological or microbial activity, relevant for assessing compound efficacy.

Recommended In Vitro Efficacy Tests

Cdc Like Kinase 1

Cdc Like Kinase 1 (CLK1) is implicated in liver injury via regulation of RNA splicing and cellular stress responses. Testing CLK1 activity is crucial for evaluating potential drug-induced liver toxicity. Our service employs ATP and radioactivity assays to quantify CLK1 inhibition, providing precise IC-50 values. These data support early-stage drug development by identifying compounds that may modulate CLK1 activity and contribute to liver safety profiles.

Pharmacological Activity Material Method Parameter
Serine/threonine protein kinase (ClK1), inhibition Human enzyme Radioactivity assay IC-50
Serine/threonine protein kinase (ClK1), inhibition Human enzyme IC-50
Serine/threonine protein kinase (ClK1), inhibition ATP assay IC-50
Serine/threonine protein kinase (ClK1), inhibition IC-50

Cdc Like Kinase 2

Cdc Like Kinase 2 (CLK2) regulates RNA splicing and hepatocyte survival, making it a key target in liver injury research. Testing CLK2 activity is crucial for evaluating drug candidates’ effects on liver injury pathways. Our service employs sensitive radioactivity assays to measure CLK2 inhibition, providing quantitative IC-50 values. This enables precise assessment of compound potency, supporting the development of safer, more effective liver injury therapeutics.

Pharmacological Activity Material Method Parameter
Serine/threonine protein kinase (ClK2), inhibition Human enzyme Radioactivity assay IC-50
Serine/threonine protein kinase (ClK2), inhibition Human enzyme IC-50

E1A Binding Protein P300

E1A Binding Protein P300 is a transcriptional co-activator implicated in liver injury by regulating genes involved in inflammation and fibrosis. Testing its activity is crucial for evaluating therapeutic candidates in liver injury drug development. Our service employs a sensitive fluorescent assay to quantify p300 inhibition, providing precise IC-50 values to assess compound potency and efficacy. This enables informed decision-making in early-stage drug discovery.

Pharmacological Activity Material Method Parameter
Histone acetyltransferase P300 (HAT domain), inhibition Recombinant enzyme Fluorescent assay IC-50

Histone Deacetylase 6

Histone Deacetylase 6 (HDAC6) plays a crucial role in liver injury by modulating cellular stress and inflammatory responses. HDAC6 testing is vital for evaluating drug candidates targeting liver injury, aiding in the identification of effective modulators. Our service uses a chemiluminescent assay with Acetyl-Arg-Gly-Lys (Ac)-7-amido-4-methylcoumarin as the substrate. Key parameters measured include EC-50, IC-50, and MIC, providing quantitative insights into compound potency and efficacy.

Pharmacological Activity Material Method Parameter
Histone deacetylase 6 degradation, induction EC-50
Histone deacetylase 6 expression, inhibition AML12 mouse hepatocytes (paracetamol-treated) Chemiluminescent assay MIC
Histone deacetylase 6, inhibition Acetyl-Arg-Gly-Lys (Ac)-7-amido-4-methylcoumarin as substrate IC-50

Interleukin 1 Beta

Interleukin 1 Beta (IL-1β) is a key pro-inflammatory cytokine implicated in liver injury and drug-induced hepatotoxicity. Accurate IL-1β testing is crucial for evaluating inflammatory responses during liver injury drug development. Our service uses sensitive chemiluminescent and RNA assays to quantify IL-1β expression. The minimum inhibitory concentration (MIC) is a main parameter assessed, ensuring reliable measurement of drug effects on IL-1β-mediated liver inflammation.

Pharmacological Activity Material Method Parameter
Gene (interleukin-1 beta) transcription (endotoxin-induced), inhibition Kupffer cells, rat RNA assay MIC
Gene (interleukin-1 beta) transcription (endotoxin-induced), inhibition RAW264.7 mouse macrophages RNA assay MIC
Interleukin-1beta expression (endotoxin/ATP-induced), inhibition Macrophages (THP1 human acute monocytic leukemia cells-derived) Chemiluminescent assay MIC
Interleukin-1beta expression (leptin-induced), inhibition MCF7 human breast adenocarcinoma cells (hormone-dependent) Chemiluminescent assay MIC
Interleukin-1beta expression, inhibition AML12 mouse hepatocytes (paracetamol-treated) Chemiluminescent assay MIC

Janus Kinase 1

Janus Kinase 1 (JAK1) is a key mediator in inflammatory signaling pathways implicated in liver injury. Testing JAK1 activity is crucial for evaluating potential therapeutics targeting liver injury mechanisms. Our service utilizes a sensitive radioactivity assay to quantify JAK1 inhibition, providing precise measurement of IC-50 values. This enables effective assessment of drug candidates’ potency and supports informed decision-making in liver injury drug development.

Pharmacological Activity Material Method Parameter
Protein-tyrosine kinase (JAK1), inhibition Human enzyme Radioactivity assay IC-50
Protein-tyrosine kinase (JAK1), inhibition Human enzyme IC-50

Janus Kinase 2

Janus Kinase 2 (JAK2) plays a crucial role in inflammatory signaling pathways implicated in liver injury. Testing JAK2 activity is essential for evaluating potential drug candidates targeting liver diseases. Our service utilizes a sensitive radioactivity assay to measure JAK2 inhibition, determining the half-maximal inhibitory concentration (IC-50) as a key parameter. This enables precise assessment of compound efficacy in modulating JAK2-driven liver injury mechanisms during drug development.

Pharmacological Activity Material Method Parameter
Protein-tyrosine kinase (JAK2), inhibition Human enzyme Radioactivity assay IC-50
Protein-tyrosine kinase (JAK2), inhibition Human enzyme IC-50

Kelch Like Ech Associated Protein 1

Kelch Like Ech Associated Protein 1 (Keap1) regulates oxidative stress responses implicated in liver injury. Testing Keap1 is crucial in drug development to assess hepatotoxicity risk and antioxidant pathway activation. Key methods include Western blot, ELISA, and immunohistochemistry to quantify and localize Keap1. Main parameters measured are Keap1 protein levels, localization, and interactions with Nrf2, providing insight into oxidative stress modulation and potential drug-induced liver injury.

Pharmacological Activity Method Parameter
Kelch-like ECH-associated protein 1 (INrf2) affinity Biolayer interferometry assay Kd
Kelch-like ECH-associated protein 1 (INrf2) affinity Isothermal titration calorimetric assay Kd

Mitogen-Activated Protein Kinase Kinase Kinase 5

Mitogen-Activated Protein Kinase Kinase Kinase 5 (MAP3K5) plays a key role in liver injury by regulating apoptosis and stress response pathways. Testing MAP3K5 activity is crucial for developing hepatoprotective drugs and assessing toxicity. Our service utilizes a sensitive radioactivity assay to measure MAP3K5 inhibition, providing precise IC-50 values for candidate compounds. This enables efficient screening and optimization of therapeutics targeting liver injury mechanisms.

Pharmacological Activity Material Method Parameter
Serine/threonine kinase (mitogen-activated protein kinase kinase kinase 5 [MAP3K5]), inhibition Human enzyme Radioactivity assay IC-50
Serine/threonine kinase (mitogen-activated protein kinase kinase kinase 5 [MAP3K5]), inhibition Human enzyme IC-50

Nfe2 Like Bzip Transcription Factor 2

Nfe2 Like Bzip Transcription Factor 2 (Nrf2) regulates cellular defense against oxidative stress, a key factor in liver injury. Testing Nrf2 activation is essential in drug development to assess hepatoprotective or hepatotoxic effects. Key methods include luciferin/luciferase, RNA, fluorescent, and chemiluminescent assays. Main parameters measured are MEC (minimum effective concentration), IC50 (half maximal inhibitory concentration), and MIC (minimum inhibitory concentration), enabling precise evaluation of drug safety and efficacy.

Pharmacological Activity Material Method Parameter
Gene (nuclear factor erythroid 2-related factor 2 (NRF2)) transcription, induction HepG2 human hepatoblastoma cells transfected with antioxidant response element//luciferase Luciferine/luciferase assay MEC
Gene (nuclear factor erythroid 2-related factor 2 (NRF2)) transcription, induction L02 human liver cells RNA assay MEC
Nuclear factor erythroid 2-related factor 2 (NRF2) expression decrease (tert-butylhydroperoxide-induced), inhibition HepG2 human hepatoblastoma cells Chemiluminescent assay MIC
Nuclear factor erythroid 2-related factor 2 (NRF2)/Keap1 Kelch domain interaction, inhibition Fluorescent assay IC-50
Protein (nuclear factor erythroid 2-related factor 2 (NRF2)) expression, induction HepG2 human hepatoblastoma cells Chemiluminescent assay MEC

Nuclear Receptor Subfamily 1 Group H Member 4

Nuclear Receptor Subfamily 1 Group H Member 4 (NR1H4), also known as FXR, regulates bile acid homeostasis and is pivotal in liver injury mechanisms. Testing NR1H4 activity is crucial for evaluating drug-induced liver injury risk. Key methods include SRC-1 and SRC-2-2 peptide recruitment assays, cell-based assays, luciferin/luciferase, and chemiluminescent assays. Main parameters measured are EC-50 and IC-50, indicating compound potency and inhibitory effects.

Pharmacological Activity Material Method Parameter
Farnesoid FXR receptor activation, induction HepG2 human hepatoblastoma cells SRC-1 peptide recruitment assay EC-50
Farnesoid FXR receptor activation, inhibition SRC-2-2 peptide recruitment assay IC-50
Farnesoid FXR receptor/SRC1 coactivator interaction, induction Recombinant human receptor Cell-based assay EC-50
Farnesoid FXR receptor/SRC1 coactivator interaction, induction Recombinant human receptor Chemiluminescent assay EC-50
Gene (FXR) transcription, induction HepG2 human hepatoblastoma cells transfected with human receptor Luciferine/luciferase assay EC-50
Gene transcription (FXR-dependent), induction HEK293T human embryonic kidney cells transfected with FXR receptor Luciferine/luciferase assay EC-50

Pannexin 1

Pannexin 1 is implicated in mediating inflammation and cell death during liver injury. Testing its function is essential for evaluating potential therapeutics targeting liver damage mechanisms. Our Pannexin 1 testing service employs a sensitive flow cytometry assay to quantify channel activity and assess drug effects. Key parameters measured include the dissociation constant (Kd), providing critical insights into drug binding affinity and efficacy in liver injury drug development.

Pharmacological Activity Material Method Parameter
Pannexin-1 affinity Dubca camel skin fibroblasts transfected with human protein Flow cytometry assay Kd
Pannexin-1 affinity Dubca camel skin fibroblasts transfected with mouse protein Flow cytometry assay Kd
HOW WE WORK

Make Order

Make Order

Experimental Scheme

Experimental Scheme

Implementation

Implementation

Conclusion

Conclusion
Make an Inquiry